View in EDS

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Saved in:

Bibliographic Details
Title:	Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
Authors:	Liu MA; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA. Michael.liu1@northwestern.edu., Miyazaki K; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA., Runcie K; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA., Cash H; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA., Meng L; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Source:	Targeted oncology [Target Oncol] 2026 May 31. Date of Electronic Publication: 2026 May 31.
Publication Type:	Journal Article
Journal Info:	Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1776-260X
DOI:	10.1007/s11523-026-01228-x